Skip to content
Go to home page
Join
  1. Home
  2. News and press releases
  3. Geir Hetland joins the board of Oslo Cancer Cluster

Geir Hetland joins the board of Oslo Cancer Cluster

Geir Hetland, Chief Financial Officer of Thermo Fisher Scientific, is the latest addition to the board of Oslo Cancer Cluster.

Two men in business attire are standing in front of a construction site, smiling at the camera. They are wearing suits and light blue shirts, with one man sporting glasses. Behind them, the construction site is fenced off with metal barriers, and various building materials and equipment are visible, including a concrete mixer and wooden support structures. The sunny weather casts shadows, and the overall setting suggests they are visiting or inspecting the progress of the construction project. The image conveys a blend of business and industry.
Geir Hetland, Chief Financial Officer of Thermo Fisher Scientific and new board member of Oslo Cancer Cluster, with Ketil Widerberg, general manager of Oslo Cancer Cluster, in front of the construction site for the fourth tower of Oslo Cancer Cluster Innovation Park. Thermo Fisher Scientific will lease almost four floors of labs and offices in this new building - right next to the hospital and research institute. Photo: Sofia Linden / Oslo Cancer Cluster
Published

Jun 6, 2024

Author

Sofia Linden

Category
Expansion

“I wish to contribute to the strategic direction and success of Oslo Cancer Cluster. The organisation has a great foundation to further develop to become one of the leading cancer clusters worldwide,” commented Hetland after he was elected at Oslo Cancer Cluster’s general assembly last week.

Hetland brings 30 years of experience from the life science industry ranging from global companies to start-ups. He has worked 15 years for AstraZeneca, both as Chief Financial Officer in Norway and as European Business Director supporting the 7 largest European countries with base in Brussel.

Expanding the innovation park

After spending close to 14 years in Thermo Fisher Scientific, Hetland is now the company’s Chief Financial Officer. Thermo Fisher Scientific is a key player in the current expansion of Oslo Cancer Cluster Innovation Park. The company has signed a lease for nearly four floors (two lab floors and two office floors) compromising almost 75 per cent of the entire fourth tower being constructed on the western side of the premises.

“Thermo Fisher Scientific has always been located close to Radiumhospitalet (Oslo University Hospital) with close collaboration with the hospital. This has been a win-win situation for both sides, and we would like to even strengthen this further moving forward. Radiumhospitalet is the birthplace of some of the greatest innovations in multiple cancer fields bringing better cancer treatments to patients,” said Hetland.

Supporting cancer start-ups

Going forward, Hetland wishes to increase Oslo Cancer Cluster’s capacity to help start-ups so that new cancer innovations faster reach patients.

“Oslo Cancer Cluster mission is dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and treatments. This will always be the number 1 priority! To achieve this, we need to ensure that start-up companies are positioned to succeed in everything from capital funding, sufficient expansion space with research labs and all the way to readout of patient data in their clinical trials.”

Similar articles